Skip to content Skip to footer
Subscribe Now
NEWS

Merz Therapeutics Enrolls First Patients in P-III Studies Evaluating Xeomin for Migraine Prevention

Shots:Merz Therapeutics has enrolled the first patients in two global P-III studies, MINT-E (episodic migraine, ~990 pts) and MINT-C (chronic migraine, ~780 pts), evaluating the efficacy and safety of Xeomin (incobotulinumtoxinA) for migraine preventionBoth studies will recruit ~1,770 adults across 120 sites in North America & Europe, and recruitment in Europe is expected…
August 26, 2025

Read more

VIEWPOINTS_Samantha Kerr_2023
VIEWPOINTS

Samantha Kerr shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+)

Shots:Samantha Kerr, Chief Scientific Officer, Merz Aesthetics shares insights from the topline data of Xeomin P-III studies and pivotal study evaluating Belotero Balance (+)Samantha says, for Belotero Balance (+), Merz Aesthetics has already submitted the data as a supplemental Premarket Approval Application (sPMA) with the FDA and plans to submit the data as…
October 5, 2023

Read more

Viewpoint_Dr. Terri Phillips_2020
VIEWPOINTS

PharmaShots Interview: Merz Aesthetics’ Dr. Terri Phillips Shares Insight on GP Campaign for Xeomin

In an interview with PharmaShots, Dr. Terri Phillips, Chief Medical Affairs Officer at Merz Aesthetics shared her views on the new campaign with Gwyneth Paltrow for its flagship product Xeomin. She also shed light on Medical Aesthetic treatments during the pandemic and how Merz is working to meet the demand.Shots:Merz Aesthetics collaborates with Gwyneth Paltrow for the launch of the company's first…
February 27, 2020

Read more